Medical President Montgomery calls for tougher interventions in drug pricing
Pharmaceutical expenditure in Germany reached a new record high last year. According to experts, cost drivers are particularly expensive, innovative drugs for hepatitis C and combination therapies for cancer. Medical President Frank Ulrich Montgomery has now called for further interventions in the design of drug prices.
Pharmaceutical expenditure in Germany is rising and rising
Germany's doctors are prescribing more and more medication. Pharmaceutical spending by health insurance companies has also increased dramatically nationwide in recent years. According to the Techniker Krankenkasse (TK), pharmaceutical drug spending had reached a new record high in 2015. The main cost drivers are expensive innovative medicines for hepatitis C and combination therapies for cancer. Not all experts agree on how costs can be reduced. Medical President Frank Ulrich Montgomery is now calling for further interventions in the design of drug prices in Germany.
It must not be that companies "enrich themselves excessively"
According to a message from the dts news agency, Montgomery said in an interview with the news magazine "Focus": "It is not acceptable that companies that develop new medicines enrich themselves excessively in a socially bound system." The suggestions of Federal Minister of Health Hermann Gröhe (CDU ) don't go far enough for the president of the doctor: "We need further answers," says Montgomery. "But the pharmaceutical industry should hardly like that," he continued. "We advocate abolishing free, exclusively market-oriented pricing in the first year after the market launch by industry." As it is said, Health Minister Gröhe wants to introduce a threshold for expensive new drugs: If the sales value in the first year after approval is higher , the lower reimbursement price applies retrospectively. However, the minister has not yet made a definitive commitment to this level. (ad)